Phase III failure of mirvetuximab soravtansine in ovarian Cancer touches off stock price plunge for ImmunoGenInc httpow.lyUe3030nT4FSÂ

Phase III failure of mirvetuximab soravtansine in ovarian #Cancer touches off stock price plunge for @ImmunoGenInc: http://ow.ly/Ue3030nT4FS 

16:55 EST 1 Mar 2019 | Genetic Engineering News

Phase III failure of mirvetuximab soravtansine in ovarian #Cancer touches off stock price plunge for @ImmunoGenInc: http://ow.ly/Ue3030nT4FS 

More From BioPortfolio on "Phase III failure of mirvetuximab soravtansine in ovarian #Cancer touches off stock price plunge for @ImmunoGenInc: http://ow.ly/Ue3030nT4FS "